HealthEquity Inc (HQY)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $8.56B
Last updated: Nov 17, 2026 at 11:06 AM ET
HealthEquity Inc (HQY) Financials: Revenue, Profit and Cash Flow
HealthEquity reported revenue of $1.31B for the fiscal year ended Jan 31, 2026, up 9.5% from the year before. That year, net income was $215.20M with a net margin of 16.4%, operating cash flow was $457.09M and free cash flow was $408.61M. The quarter ended Jul 31, 2026 had revenue of $350.73M and net income of $65.64M.
Revenue and Margins
The operating margin was 24.6% in the fiscal year ended Jan 2026. Over the 9 years to Jan 2026, revenue grew from $178.37M, a compound annual rate of 24.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jan 2026 | $1.31B | +9.5% | 69.5% | 24.6% | 16.4% |
| Jan 2025 | $1.20B | +20.0% | 64.8% | 13.5% | 8.1% |
| Jan 2024 | $999.59M | +16.0% | 62.3% | 11.8% | 5.6% |
| Jan 2023 | $861.75M | +13.9% | 57.1% | 1.1% | -3.0% |
| Jan 2022 | $756.56M | +3.1% | 56.1% | -3.2% | -5.9% |
| Jan 2021 | $733.57M | +37.9% | 56.6% | 4.6% | 1.2% |
| Jan 2020 | $531.99M | +85.2% | 61.3% | 14.5% | 7.5% |
| Jan 2019 | $287.24M | +25.1% | 63.1% | 27.0% | 25.7% |
| Jan 2018 | $229.53M | +28.7% | 58.8% | 23.7% | 20.6% |
| Jan 2017 | $178.37M | N/A | 59.6% | 23.1% | 14.8% |
Income Statement
In the fiscal year ended Jan 2026, net income rose 122.5% from the year before. In the quarter ended Jul 2026, net income rose 9.7% from the same quarter a year earlier.
Annual
| Line item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31B | $1.20B | $999.59M | $861.75M | $756.56M | $733.57M | $531.99M | $287.24M | $229.53M | $178.37M |
| Cost of revenue | $400.31M | $422.51M | $376.95M | $369.81M | $331.79M | $318.24M | $206.08M | $106.05M | $94.61M | $72.02M |
| Gross profit | $913.12M | $777.26M | $622.64M | $491.94M | $424.76M | $415.33M | $325.91M | $181.19M | $134.92M | $106.36M |
| Research and development | $262.51M | $239.51M | $218.81M | $193.38M | $157.36M | $124.81M | $77.58M | $35.06M | $27.39M | $22.38M |
| Operating income | $322.46M | $162.33M | $117.70M | $9.06M | -$24.24M | $34.01M | $77.01M | $77.67M | $54.42M | $41.21M |
| Net income | $215.20M | $96.70M | $55.71M | -$26.14M | -$44.29M | $8.83M | $39.66M | $73.90M | $47.36M | $26.38M |
| EBITDA | $490.28M | $341.19M | $286.43M | $174.79M | $111.47M | $160.03M | $125.99M | $94.33M | $68.42M | $53.40M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $350.73M | $354.64M | $334.59M | $322.16M | $325.83M | $330.84M | $311.82M | $300.43M | $299.93M | $287.60M | $262.39M | $249.22M |
| Gross profit | $257.95M | $256.31M | $228.15M | $228.06M | $232.59M | $224.31M | $189.04M | $197.03M | $204.05M | $187.14M | $163.32M | $159.18M |
| Operating income | $98.69M | $102.95M | $71.07M | $78.69M | $89.61M | $83.08M | $42.15M | $19.63M | $58.93M | $41.63M | $38.89M | $30.89M |
| Net income | $65.64M | $69.42M | $49.74M | $51.69M | $59.85M | $53.91M | $26.36M | $5.70M | $35.82M | $28.81M | $26.36M | $14.67M |
Balance Sheet
As of Jan 2026, total debt of $967.29M exceeded cash and equivalents by $648.36M.
Annual
| Line item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.38B | $3.45B | $3.16B | $3.09B | $3.11B | $2.71B | $2.56B | $510.02M | $369.16M | $279.14M |
| Current assets | $512.28M | $477.75M | $557.44M | $382.89M | $351.34M | $460.18M | $297.30M | $394.68M | $265.40M | $200.82M |
| Cash and equivalents | $318.93M | $295.95M | $403.98M | $254.27M | $225.41M | $328.80M | $191.73M | $361.48M | $199.47M | $139.95M |
| Total liabilities | $1.27B | $1.33B | $1.13B | $1.19B | $1.25B | $1.33B | $1.53B | $32.94M | $22.89M | $17.20M |
| Short-term debt | $9.91M | $10.00M | $9.40M | $17.50M | $8.75M | $62.50M | $39.06M | $0 | N/A | N/A |
| Long-term debt | $957.38M | $1.06B | $874.97M | $907.84M | $922.08M | $924.22M | $1.18B | $0 | $0 | $0 |
| Shareholder equity | $2.11B | $2.11B | $2.04B | $1.90B | $1.85B | $1.38B | $1.03B | $477.08M | $346.27M | $261.94M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.27B | $3.31B | $3.43B | $3.40B | $3.42B | $3.42B | $3.45B | $3.49B | $3.51B | $3.25B | $3.16B | $3.09B |
| Total liabilities | $1.28B | $1.26B | $1.32B | $1.26B | $1.27B | $1.29B | $1.33B | $1.36B | $1.36B | $1.15B | $1.13B | $1.11B |
| Cash and equivalents | $256.00M | $265.37M | $318.93M | $309.26M | $304.46M | $287.89M | $295.95M | $322.16M | $326.89M | $251.23M | $403.98M | $334.06M |
| Shareholder equity | $1.99B | $2.05B | $2.11B | $2.13B | $2.15B | $2.12B | $2.11B | $2.12B | $2.16B | $2.10B | $2.04B | $1.99B |
Cash Flow
In the fiscal year ended Jan 2026, free cash flow was 89.4% of operating cash flow. Share repurchases came to 73.2% of it.
Annual
| Line item | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $457.09M | $339.86M | $242.83M | $150.65M | $141.00M | $181.62M | $105.01M | $113.42M | $81.70M | $45.59M |
| Capital expenditures | $48.48M | $53.21M | $42.82M | $48.54M | $71.62M | $64.59M | $32.94M | $13.88M | $15.84M | $12.68M |
| Free cash flow | $408.61M | $286.64M | $200.01M | $102.11M | $69.38M | $117.03M | $72.07M | $99.54M | $65.86M | $32.92M |
| Share repurchases | $299.25M | $121.49M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$47.14M | -$505.45M | -$46.07M | -$119.13M | -$639.25M | -$96.96M | -$1.74B | $25.65M | -$36.75M | -$13.05M |
| Financing cash flow | -$386.98M | $57.57M | -$47.04M | -$2.67M | $394.86M | $52.42M | $1.47B | $22.93M | $14.56M | $23.78M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $136.16M | $97.53M | $117.92M | $138.57M | $135.87M | $64.74M | $75.75M | $90.55M | $108.13M | $65.43M | $77.07M | $57.11M |
| Capital expenditures | $15.77M | $16.29M | $10.07M | $11.09M | $11.18M | $16.14M | $13.56M | $12.87M | $12.96M | $13.83M | $11.27M | $12.16M |
| Free cash flow | $120.39M | $81.23M | $107.84M | $127.49M | $124.69M | $48.59M | $62.19M | $77.69M | $95.17M | $51.60M | $65.80M | $44.95M |
Frequently Asked Questions About HQY
What is HealthEquity's annual revenue?
HealthEquity reported revenue of $1.31B for the fiscal year ended Jan 31, 2026.
How fast is HealthEquity's revenue growing?
Revenue was up 9.5% for the fiscal year ended Jan 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 15.1%.
Is HealthEquity profitable?
Yes. HealthEquity reported net income of $215.20M for the fiscal year ended Jan 31, 2026, with a net margin of 16.4%.
How much free cash flow does HQY generate?
For the fiscal year ended Jan 31, 2026, operating cash flow of $457.09M minus capital expenditures of $48.48M produced free cash flow of $408.61M.
How much debt does HealthEquity have?
The balance sheet dated Jan 31, 2026 reported long-term debt of $957.38M, short-term debt of $9.91M and cash and equivalents of $318.93M.
HQY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts